Key Highlights

• LABT shares surged 8.15% intraday to $3.40.

• The company appointed a globally recognized diabetic foot care expert as Study Chair for its Phase 2a Nu-3 trial.

• Nu-3 is being evaluated as a topical antimicrobial for infected diabetic foot ulcers.

• Lakewood-Amedex carries a market capitalization of approximately $1.59 million.

Expert Appointment Lifts Shares

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) shares surged Wednesday after the company announced the appointment of a globally recognized diabetic foot care expert as Study Chair for its Phase 2a clinical trial evaluating Nu-3 in infected diabetic foot ulcers, who will also serve as a Scientific Advisor to the program.

Lakewood-Amedex is a University Park, Florida-based clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials known as the Bisphosphocin class, targeting infectious diseases including antibiotic-resistant pathogens such as MRSA and VRE.

Trial Evaluates Three Dose Concentrations

The Phase 2a proof-of-concept trial will evaluate three dose concentrations of topical Nu-3 gel, 2%, 5% and 10%, in patients with infected diabetic foot ulcers, and is designed to support advancement into a larger Phase 2b study. The newly appointed Study Chair is a distinguished professor of surgery and neurological surgery who has authored hundreds of peer-reviewed publications on diabetic foot care, wound healing and limb preservation.

Lakewood-Amedex currently trades at a market capitalization of approximately $1.59 million, reflecting its early clinical-stage, micro-cap profile.

Conclusion

The addition of a leading diabetic foot care expert to oversee the Phase 2a Nu-3 trial adds scientific credibility to Lakewood-Amedex's antimicrobial development program, addressing a persistent clinical challenge complicated by rising antibiotic resistance. As a micro-cap, early-stage biotechnology company, continued trial progress will remain the key catalyst determining the stock's trajectory.

 

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.